Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Protagenic Therapeutics ( (PTIX) ) is now available.
Protagenic Therapeutics announced a 1-for-14 reverse stock split of its common stock, effective May 5, 2025, to comply with Nasdaq’s minimum bid price requirement. This move will reduce the number of outstanding shares significantly, impacting shareholders by consolidating their shares, and is intended to maintain the company’s listing on Nasdaq.
Spark’s Take on PTIX Stock
According to Spark, TipRanks’ AI Analyst, PTIX is a Underperform.
Protagenic Therapeutics faces significant financial difficulties, with no revenue and persistent losses. Technical indicators suggest weak market momentum, and the company’s valuation is unattractive due to negative earnings. These factors collectively result in a low overall stock score, reflecting substantial risks and challenges.
To see Spark’s full report on PTIX stock, click here.
More about Protagenic Therapeutics
Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on developing neuro-active peptides into therapeutics aimed at mitigating stress-related disorders.
YTD Price Performance: -58.08%
Average Trading Volume: 5,372,062
Technical Sentiment Signal: Buy
Current Market Cap: $1.64M
For detailed information about PTIX stock, go to TipRanks’ Stock Analysis page.